Publications by authors named "Taina Turpeenniemi-Hujanen"

86Publications

Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma.

Ann Hematol 2020 Aug 23;99(8):1823-1831. Epub 2020 Jun 23.

Medical Research Center, Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Kajaanintie 50, P.O. Box 5000, 900l4, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-020-04140-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340636PMC
August 2020

Prognostic significance of Twist, ZEB1 and Slug in peripheral T-cell lymphomas.

Hematology 2020 Dec;25(1):241-246

Department of Oncology and Radiotherapy, Oulu University Hospital and University of Oulu, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/16078454.2020.1780754DOI Listing
December 2020

Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment.

Eur J Haematol 2020 Aug 16;105(2):156-163. Epub 2020 Apr 16.

Department of Oncology, Faculty of Health Medicine, Institute of Clinical Medicine, Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13419DOI Listing
August 2020

Significance of bulky mass and residual tumor-Treated with or without consolidative radiotherapy-To the risk of relapse in DLBCL patients.

Cancer Med 2020 Mar 22;9(6):1966-1977. Epub 2020 Jan 22.

Faculty of Health Medicine, Department of Oncology, Institute of Clinical Medicine, Kuopio University Hospital, University of Eastern Finland, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2798DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064117PMC
March 2020

Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects.

Anticancer Res 2019 Oct;39(10):5559-5564

Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13749DOI Listing
October 2019

Peroxiredoxin 6 Serum Levels and Risk of Neutropenic Infections in Diffuse Large B-cell Lymphoma.

Anticancer Res 2019 Sep;39(9):4925-4931

Department of Oncology, Faculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13680DOI Listing
September 2019

Treatment of diffuse large B-cell lymphoma in elderly patients: Replacing doxorubicin with either epirubicin or etoposide (VP-16).

Hematol Oncol 2019 Apr 18;37(2):136-142. Epub 2019 Jan 18.

Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hon.2572
Publisher Site
http://dx.doi.org/10.1002/hon.2572DOI Listing
April 2019

Case Report: Chemotherapy in Conjunction With Blood-Brain Barrier Disruption for a Patient With Germ Cell Tumor With Multiple Brain Metastases.

Clin Genitourin Cancer 2018 10 26;16(5):e993-e996. Epub 2018 May 26.

Department of Oncology, Medical Research Center, University of Oulu, Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183037
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.05.005DOI Listing
October 2018

Strong Prolyl Hydroxylase Domain 1 Expression Predicts Poor Outcome in Radiotherapy-treated Patients with Classical Hodgkin's Lymphoma.

Anticancer Res 2018 01;38(1):329-336

Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital, Oulu, Finland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.12226DOI Listing
January 2018

Low Rap1-interacting factor 1 and sirtuin 6 expression predict poor outcome in radiotherapy-treated Hodgkin lymphoma patients.

Leuk Lymphoma 2018 03 8;59(3):679-689. Epub 2017 Aug 8.

a Department of Oncology and Radiotherapy , Medical Research Center Oulu, Oulu University Hospital and Cancer and Translational Medicine Research Unit, University of Oulu , Oulu , Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1344840DOI Listing
March 2018

Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma.

Anticancer Res 2016 09;36(9):4677-83

Department of Oncology and Radiotherapy, Oulu University Hospital and University of Oulu, Oulu, Finland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.11020DOI Listing
September 2016

Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma.

Virchows Arch 2016 May 16;468(5):623-30. Epub 2016 Mar 16.

Department of Oncology and Radiotherapy, University of Oulu and Medical Research Center, Oulu University Hospital, P.O. Box 22, 90029, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-016-1920-2DOI Listing
May 2016

Antithrombin III is probably not a suitable biomarker for diagnosis of primary central nervous system lymphoma.

Ann Hematol 2015 Jul 21;94(7):1167-74. Epub 2015 Feb 21.

Department of Oncology and Radiotherapy, University of Oulu, Medical Research Center, and Oulu University Hospital, Kajaanintie 50, 90220, Oulu, Finland,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-015-2334-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432105PMC
July 2015

Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas.

Histopathology 2014 Sep 3;65(3):319-27. Epub 2014 Apr 3.

Department of Oncology and Radiotherapy, Oulu University Hospital and University of Oulu, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12389DOI Listing
September 2014

Increased expression of CIP2A in aggressive subtypes of B-cell lymphoma.

Histopathology 2013 Sep 26;63(3):438-9. Epub 2013 Jun 26.

Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.12162DOI Listing
September 2013

Cell cycle regulation score predicts relapse-free survival in non-germinal centre diffuse large B-cell lymphoma patients treated by means of immunochemotherapy.

Eur J Haematol 2013 Jul 3;91(1):29-36. Epub 2013 May 3.

Department of Oncology and Radiotherapy, University of Oulu and Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12117DOI Listing
July 2013

Circulating matrix metalloproteinase MMP-9 and MMP-2/TIMP-2 complex are associated with spontaneous early pregnancy failure.

Reprod Biol Endocrinol 2013 Jan 15;11. Epub 2013 Jan 15.

Department of Obstetrics and Gynecology, Oulu University Hospital, Kajaanintie 52A, Oulu, 90220, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1477-7827-11-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566964PMC
January 2013

Snail promotes an invasive phenotype in lung carcinoma.

Respir Res 2012 Nov 17;13:104. Epub 2012 Nov 17.

Department of Internal Medicine, Respiratory Research Unit, University of Oulu and Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1465-9921-13-104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546026PMC
November 2012

Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma.

Tumour Biol 2012 Aug 21;33(4):935-41. Epub 2012 Jan 21.

Department of Obstetrics and Gynecology, University of Oulu, PO Box 5000, 90014 Oulu, Finland.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13277-012-0321-7
Publisher Site
http://dx.doi.org/10.1007/s13277-012-0321-7DOI Listing
August 2012

Long-term prognosis of breast cancer detected by mammography screening or other methods.

Breast Cancer Res 2011 28;13(6):R134. Epub 2011 Dec 28.

Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Biomedicum Helsinki 2U, Tukholmankatu 8, PO Box 20, FI-00014 Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr3080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326576PMC
June 2012

Expression and prognostic evaluation of oxidative stress markers in an immunohistochemical study of B-cell derived lymphomas.

Leuk Lymphoma 2012 Apr 13;53(4):624-31. Epub 2011 Dec 13.

Department of Oncology and Radiotherapy, University of Oulu and Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2011.624226DOI Listing
April 2012

8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma.

Int J Clin Exp Pathol 2011 Mar 2;4(3):267-75. Epub 2011 Mar 2.

Department of Clinical Pathology and Forensic Medicine, Institute of Clinical Medicine, School of Medicine, Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071659PMC
March 2011

A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53.

Hum Pathol 2011 Aug 21;42(8):1103-11. Epub 2011 Feb 21.

Department of Oncology and Radiotherapy, Oulu University Hospital, OYS 90029, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2010.11.013DOI Listing
August 2011

p53 in head and neck cancer: functional consequences and environmental implications of TP53 mutations.

Head Neck Oncol 2010 Dec 15;2:36. Epub 2010 Dec 15.

Institute of Clinical Medicine, Department of Oncology and Radiotherapy, University of Oulu, Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1758-3284-2-36DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022569PMC
December 2010

Levels of Circulating TIMP-2 and MMP2-TIMP2 Complex Are Decreased in Squamous Cervical Carcinoma.

Obstet Gynecol Int 2010 29;2010:179351. Epub 2010 Jun 29.

Department of Obstetrics and Gynecology, Oulu University Hospital, University of Oulu, P.O. Box 24, 90029 OYS Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2010/179351DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910473PMC
July 2011

Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial.

Anticancer Res 2010 Mar;30(3):1001-6

Department of Oncology and Radiotherapy, P.O. Box 22, FIN-90029 Oulu University Hospital, Finland.

View Article

Download full-text PDF

Source
March 2010

High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.

Anticancer Res 2008 Sep-Oct;28(5A):2715-9

Department of Obstetrics and Gynecology, University of Oulu, Oulu, Finland.

View Article

Download full-text PDF

Source
December 2008

Low circulating levels of ProMMP-2 are associated with adverse prognosis in bladder cancer.

Tumour Biol 2008 19;29(5):279-86. Epub 2008 Sep 19.

Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000156705DOI Listing
January 2009

Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis.

Anticancer Res 2008 May-Jun;28(3B):1757-61

Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
July 2008

Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.

Eur J Haematol 2008 Oct 8;81(4):289-97. Epub 2008 Jul 8.

Department of Oncology and Radiotherapy, University of Oulu and Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0609.2008.01113.xDOI Listing
October 2008

High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma.

Int J Cancer 2008 Aug;123(4):846-51

Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.23531DOI Listing
August 2008

Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma.

Hum Pathol 2008 Mar 9;39(3):377-85. Epub 2008 Jan 9.

Department of Oncology and Radiotherapy, Oulu University Hospital, OYS Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2007.06.021DOI Listing
March 2008

Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma.

Eur J Haematol 2008 Jan 19;80(1):46-54. Epub 2007 Nov 19.

Department of Oncology and Radiotherapy, University of Oulu and Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0609.2007.00975.xDOI Listing
January 2008

Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.

Anticancer Res 2007 Jul-Aug;27(4C):2753-8

Department of Obstetrics and Gynaecology, University of Oulu, Box 24, 90029 OYS, Finland.

View Article

Download full-text PDF

Source
August 2007

Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer.

Clin Biochem 2007 Jun 8;40(9-10):640-4. Epub 2007 Feb 8.

Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinbiochem.2007.01.021DOI Listing
June 2007

The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer.

Anticancer Res 2006 Nov-Dec;26(6C):4779-84

Department of Obstetrics and Gynaecology, University Hospital of Oulu, Oulu, Finland.

View Article

Download full-text PDF

Source
January 2007

Generalisability of survival estimates for patients with breast cancer--a comparison across two population-based series.

Eur J Cancer 2006 Dec 2;42(18):3228-35. Epub 2006 Oct 2.

Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, P.O.Box 180, FIN-00029 Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2006.06.028DOI Listing
December 2006

Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma.

Hum Pathol 2006 Oct 26;37(10):1316-23. Epub 2006 Jul 26.

Department of Oncology and Radiotherapy, Oulu University Hospital, University of Oulu, PO Box 22, FIN-90029 OYS, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2006.04.021DOI Listing
October 2006

The effects of impact and non-impact exercise on circulating markers of collagen remodelling in humans.

J Sports Sci 2006 Aug;24(8):843-8

Department of Physical Education and Sport Sciences, University of Limerick, Limerick, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/02640410500231470DOI Listing
August 2006

Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma--tissue immunoreactivity predicts aggressive clinical course.

Mod Pathol 2006 Feb;19(2):208-17

Department of Oncology and Radiotherapy, University of Oulu and Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.3800506DOI Listing
February 2006

Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma.

Anticancer Res 2005 Nov-Dec;25(6B):4101-5

Department of Obstetrics and Gynaecology, University of Oulu, Oulu, Finland.

View Article

Download full-text PDF

Source
January 2006

Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein.

Clin Cancer Res 2005 May;11(9):3257-64

Department of Oncology, University of Oulu and Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-2277DOI Listing
May 2005

Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker.

Int J Cancer 2005 Sep;116(3):422-7

Department of Oncology, University of Oulu and Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.21092DOI Listing
September 2005

Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer.

Breast Cancer Res Treat 2005 Feb;89(3):215-20

Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-004-0714-4DOI Listing
February 2005

High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma.

Breast Cancer Res Treat 2005 Jan;89(1):29-34

Department of Obstetrics and Gynaecology, University of Oulu, University Hospital of Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-004-1006-8DOI Listing
January 2005

Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma.

Cancer Lett 2005 Jan;217(2):237-42

Department of Obstetrics and Gynecology, University of Oulu and University Hospital of Oulu, Box 24, Oulu 90029 OYS, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2004.06.056DOI Listing
January 2005

Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis.

Clin Cancer Res 2004 May;10(9):3110-6

Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.ccr-03-0530DOI Listing
May 2004

Skeletal muscle collagen content in humans after high-force eccentric contractions.

J Appl Physiol (1985) 2004 Jul 27;97(1):197-203. Epub 2004 Feb 27.

Department of Physical Education and Sport Sciences, University of Limerick, Limerick, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1152/japplphysiol.01174.2003DOI Listing
July 2004

Clinicopathological correlations of TIMP-1 and TIMP-2 in Hodgkin's lymphoma.

Eur J Haematol 2004 Jan;72(1):1-9

Department of Oncology and Radiotherapy, Oulu University Hospital, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.0902-4441.2004.00168.xDOI Listing
January 2004

Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer.

Urology 2003 Nov;62(5):952-7

Department of Oncology and Radiotherapy, Oulu University Hospital and University of Oulu, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0090-4295(03)00660-5DOI Listing
November 2003

Gelatinases (MMP-2 and MMP-9), TIMP-1 expression and the extent of neovascularization in aggressive non-Hodgkin's lymphomas.

Eur J Haematol 2003 Aug;71(2):91-9

Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1034/j.1600-0609.2003.00101.xDOI Listing
August 2003

Matrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma.

Breast Cancer Res Treat 2003 Jan;77(1):85-91

Department of Oncology and Radiotherapy, University Hospital of Oulu, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1021152910976DOI Listing
January 2003

Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma.

Eur J Haematol 2002 Oct;69(4):205-12

Department of Oncology and Radiotherapy, Oulu University Hospital, Kajaanintie 50, 90220 Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1034/j.1600-0609.2002.02751.xDOI Listing
October 2002